### Wednesday, November 7, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00-18:30</td>
<td><strong>Satellite Symposium</strong>&lt;br&gt;Title: Symposium Supported by AstraZeneca - Jade Ballroom&lt;br&gt;<strong>Satellite Symposium</strong>&lt;br&gt;Title: Symposium Supported by Jiangsu Hengrui – Crystal Ballroom</td>
</tr>
</tbody>
</table>

### Thursday, November 8, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-19:00</td>
<td><strong>Poster Display</strong>&lt;br&gt;Title: Poster display reception at Meeting Room 9</td>
</tr>
<tr>
<td>08:00-08:15</td>
<td><strong>Opening Ceremony</strong>&lt;br&gt;Giorgio Scagliotti, Italy, Yi-Long Wu, China; Jie He, China</td>
</tr>
<tr>
<td>08:15-08:40</td>
<td><strong>Optimal sequence of EGFR TKI’s in patients with EGFR mutations</strong>&lt;br&gt;Tony Mok, Hong Kong</td>
</tr>
<tr>
<td>08:40-09:05</td>
<td><strong>Optimal sequence of ALK TKI’s in patients with ALK translocations</strong>&lt;br&gt;Ignatius Ou, USA</td>
</tr>
<tr>
<td>09:05-09:30</td>
<td><strong>Clinical application of ctDNA in management of oncogenic driven lung cancer</strong>&lt;br&gt;Shun Lu, China</td>
</tr>
<tr>
<td>09:30-09:55</td>
<td><strong>The reality of adjuvant/neoadjuvant targeted therapy for resectable lung cancer</strong>&lt;br&gt;Yi-Long Wu, China</td>
</tr>
<tr>
<td>09:55-10:20</td>
<td><strong>How to overcome TKI resistance?</strong>&lt;br&gt;James Chih-Hsin Yang, Taipei</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>10:40-10:55</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>10:55-11:05</td>
<td><strong>Best abstracts selected from submissions</strong>&lt;br&gt;Co-Chairs: Christian Manegold, Germany; Chun-Xue Bai, China</td>
</tr>
<tr>
<td>10:55-11:15</td>
<td><strong>LKB1 Pathway Variant TSC2 rs30259 Predicts the Prognosis in Early Stage Non-Small Cell Lung Cancer</strong>&lt;br&gt;Eungbae Lee, Korea</td>
</tr>
<tr>
<td>11:05-11:15</td>
<td><strong>Targeted Next-Generation Sequencing Reveals Relapse-Associated Genomic Alterations in Early Stage Non-Small Cell Lung Cancer</strong>&lt;br&gt;William C. Cho, Hong Kong</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td><strong>Discussant</strong>&lt;br&gt;Keunchil Park, Korea</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:15-13:45</td>
<td>Type: Satellite Symposia</td>
</tr>
<tr>
<td></td>
<td>Title: Symposium Supported by Shanghai Tongshu - Jade Ballroom</td>
</tr>
<tr>
<td></td>
<td>Type: Satellite Symposia</td>
</tr>
<tr>
<td></td>
<td>Title: Symposium Supported by Roche - Crystal Ballroom 1</td>
</tr>
<tr>
<td></td>
<td>Type: Satellite Symposia</td>
</tr>
<tr>
<td></td>
<td>Title: Symposium Supported by Pfizer - Crystal Ballroom 2</td>
</tr>
<tr>
<td></td>
<td>Type: Satellite Symposia</td>
</tr>
<tr>
<td></td>
<td>Title: Symposium Supported by Boehringer Ingelheim - Crystal Ballroom 3</td>
</tr>
<tr>
<td>13:45</td>
<td>Parallel Session 1 – Jade Ballroom</td>
</tr>
<tr>
<td></td>
<td>Biomarker detecting for lung cancer: new technique and new opinion</td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Xiao-Qing Liu, China; Keunchil Park, Korea</td>
</tr>
<tr>
<td>14:00-14:25</td>
<td>How reliable is NGS-based genome profiling?</td>
</tr>
<tr>
<td></td>
<td>Giorgio Scagliotti, Italy</td>
</tr>
<tr>
<td>14:25-14:50</td>
<td>What is a trustworthy biomarker?</td>
</tr>
<tr>
<td></td>
<td>Christian Manegold, Germany</td>
</tr>
<tr>
<td>14:50-15:15</td>
<td>Standardization of molecular testing in China</td>
</tr>
<tr>
<td></td>
<td>Xu-Chao Zhang, China</td>
</tr>
<tr>
<td>15:15-15:40</td>
<td>Clinical application of DNA methylation, in management of lung cancer</td>
</tr>
<tr>
<td></td>
<td>Shannon Chuai, China</td>
</tr>
<tr>
<td>15:40-16:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>16:00-16:20</td>
<td>Coffee break</td>
</tr>
<tr>
<td></td>
<td>Best abstracts selected from submissions</td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Yun Fan, China; Bo Zhu, China</td>
</tr>
<tr>
<td>16:20-16:30</td>
<td>Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study</td>
</tr>
<tr>
<td></td>
<td>James Chih-Hsin Yang, Taipei</td>
</tr>
<tr>
<td>16:30-16:40</td>
<td>Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs</td>
</tr>
<tr>
<td></td>
<td>Takaaki Mizuno, Japan</td>
</tr>
<tr>
<td>16:40-17:00</td>
<td>Discussant</td>
</tr>
<tr>
<td></td>
<td>Jie Hu, China</td>
</tr>
<tr>
<td></td>
<td>Parallel Session 2 – Crystal Ballroom 1</td>
</tr>
<tr>
<td></td>
<td>Brain metastases and Leptomeningeal metastasis</td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Jian-Hua Chang, China; Robert Pirker, Austria</td>
</tr>
<tr>
<td>14:00-14:25</td>
<td>Is MRI a mandatory procedure for diagnosis of CNS metastasis?</td>
</tr>
<tr>
<td></td>
<td>Daniel Tan, Singapore</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>14:25-14:50</td>
<td>Optimal radiotherapy for CNS metastasis in patients with a driver oncogene&lt;br&gt;You Lu, China</td>
</tr>
<tr>
<td>14:50-15:15</td>
<td>Can this drug penetrate the brain?&lt;br&gt;Feng-Ming Kong, USA</td>
</tr>
<tr>
<td>15:15-15:40</td>
<td>Diagnosis and management of leptomeningeal metastasis&lt;br&gt;Jin-Ji Yang, China</td>
</tr>
<tr>
<td>15:40-16:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>16:00-16:20</td>
<td>Coffee break</td>
</tr>
<tr>
<td></td>
<td><strong>Best abstracts selected from submissions</strong></td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Daniel Tan, Singapore; Di Zheng, China</td>
</tr>
<tr>
<td>16:20-16:30</td>
<td>Tumor Mutational Burden Standardization Initiative: Establish a Consistent Methodology for TMB Measurement in Clinical Samples&lt;br&gt;Albrecht Stenzinger, Germany</td>
</tr>
<tr>
<td>16:30-16:40</td>
<td>Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress&lt;br&gt;Terufumi Kato, Japan</td>
</tr>
<tr>
<td>16:40-17:00</td>
<td>Discussant&lt;br&gt;Bao-Hui Han, China</td>
</tr>
<tr>
<td></td>
<td><strong>Parallel Session 3 – Crystal Ballroom 3</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Tobacco control, Staging and cancer prevention in Asia</strong></td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Sumitra Thongprasert, Thailand; Chang-li Wang, China</td>
</tr>
<tr>
<td>14:00-14:20</td>
<td>Tobacco control in China&lt;br&gt;Xiu-Yi Zhi, China</td>
</tr>
<tr>
<td>14:20-14:40</td>
<td>Lung cancer screening in China&lt;br&gt;Ning Wu, China</td>
</tr>
<tr>
<td>14:40-15:00</td>
<td>Lung cancer screening in Asia&lt;br&gt;Sumitra Thongprasert, Thailand</td>
</tr>
<tr>
<td>15:00-15:20</td>
<td>Lung cancer staging: change and challenge&lt;br&gt;Hisao Asamura, Japan</td>
</tr>
<tr>
<td>15:20-15:40</td>
<td>Plasma-based molecular testing for early detection of lung cancer&lt;br&gt;Eric Fung, USA</td>
</tr>
<tr>
<td>15:40-15:55</td>
<td>Discussion</td>
</tr>
<tr>
<td>15:55-16:10</td>
<td>Coffee break</td>
</tr>
<tr>
<td></td>
<td><strong>Meet the JTO Editor-in-Chief</strong></td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Seiji Niho, Japan; Li Zhang, China</td>
</tr>
<tr>
<td>16:10-16:30</td>
<td>How to get your manuscript published in JTO&lt;br&gt;Alex A. Adjei, USA</td>
</tr>
<tr>
<td>16:30-16:50</td>
<td>How to write a manuscript&lt;br&gt;Tony Mok, Hong Kong</td>
</tr>
<tr>
<td>16:50-17:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 17:30-19:00      | Type: Satellite Symposia  
Title: Symposium Supported by Chia Tai Tianqing – Jade Ballroom |
|                  | Type: Satellite Symposia  
Title: Symposium Supported by Burning Rock Dx - Crystal Ballroom 3 |
| 20:00-22:00      | President’s Private Dinner                                           |

**Friday, November 9, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 07:00-19:00      | Type: Poster Display  
Title: Poster display reception at Meeting 9  |

**Plenary session – Crystal Ballroom**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:30-8:55           | Walking through the maze of first line immunotherapy for advanced NSCLC  
Fred R. Hirsch, USA |
| 8:55-9:20           | Mechanisms and management of resistance to immune checkpoint therapy  
Navneet Singh, India |
| 9:20-9:45           | PDL1 expression versus TMB: Which should we use?  
Gen Lin, China |
| 9:45-10:10          | Development of immunotherapy in China  
Qing Zhou, China |
| 10:10-10:30         | Discussion                                                               |
| 10:30-10:50         | Coffee break                                                             |
| 10:50-11:00         | Best abstracts selected from submissions  
Co-Chairs: James Chih-Hsin Yang, Taipei; Mei-Lin Liao, China  |
| 11:00-11:10         | Clinical Characterization Of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers  
Zhe-Feng Liu, China |
| 11:00-11:10         | Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-Small Cell Lung Cancer  
Ke-Jing Ying, China |
| 11:10-11:30         | Discussant  
Jiu-Wei Cui, China |
| 12:15-13:45         | Type: Satellite Symposia  
Title: Symposium Supported by prIME Oncology - Jade Ballroom  |
|                     | Type: Satellite Symposia  
Title: Symposium Supported by Bristol-Myers Squibb - Crystal Ballroom 1 |
### Parallel Session 1 – Jade Ballroom

**Parallel Session 1** New strategy for neoadjuvant and adjuvant therapy  
Co-Chairs: Paul Bunn, USA; Yong Song, China

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:25</td>
<td>New perspectives on neoadjuvant and adjuvant chemotherapy</td>
<td>Paul Bunn, USA</td>
</tr>
<tr>
<td>14:25-14:50</td>
<td>New perspectives on neoadjuvant and adjuvant targeted therapy</td>
<td>Wen-Zhao Zhong, China</td>
</tr>
<tr>
<td>14:50-15:15</td>
<td>New perspectives on neoadjuvant and adjuvant immunotherapy</td>
<td>Robert Pirker, Austria</td>
</tr>
<tr>
<td>15:15-15:40</td>
<td>Predicting and monitoring biomarkers for early stage NSCLC</td>
<td>Seiji Niho, Japan</td>
</tr>
<tr>
<td>15:40-16:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:00-16:20</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

**Best abstracts selected from submissions**  
Co-Chairs: Navneet Singh, India; Ming-Fang Zhao, China

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:20-16:30</td>
<td>High-dose icotinib in advanced NSCLC with EGFR 21 L858R mutation: a randomized, open-label phase II study</td>
<td>Xi Li, China</td>
</tr>
<tr>
<td>16:30-16:40</td>
<td>Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer</td>
<td>Ying Cheng, China</td>
</tr>
<tr>
<td>16:40-17:00</td>
<td>Discussant</td>
<td>Yong Song, China</td>
</tr>
</tbody>
</table>

### Parallel Session 2 – Crystal Ballroom 1

**Parallel Session 2** New strategy for local advanced NSCLC  
Co-Chairs: Thanyanan Reungwetwattana, Thailand; Jie Wang, China

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:25</td>
<td>New wine in old bottle: Should be apply the old data for stage III oncogenic driven lung cancer</td>
<td>Fan Yang, China</td>
</tr>
<tr>
<td>14:25-14:50</td>
<td>Immunotherapy for stage III NSCLC</td>
<td>Thanyanan Reungwetwattana, Thailand</td>
</tr>
<tr>
<td>14:50-15:15</td>
<td>New surgical techniques for stage III disease</td>
<td>Norihiko Ikeda, Japan</td>
</tr>
<tr>
<td>15:15-15:40</td>
<td>Optimal RT for local advanced NSCLC</td>
<td>Min Fan, China</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Abstract</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>15:40-16:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:00-16:20</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>
| 16:20-16:30      | **Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer**  
                   Sai-Hong I. Ou, USA                                                               |
| 16:30-16:40      | **CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)**  
                   Yi-Long Wu, China                                                               |
| 16:40-17:00      | Discussant                                                                       |
|                  | Jie Wang, China                                                                  |
| **Parallel Session 3 – Crystal Ballroom 3**                                                                 |
| Parallel Session 3 | SCLC: developments and challenges                                                |
|                  | Co-Chairs: Chong Kin Liam, Malaysia; Ying Cheng, China                            |
| 14:00-14:25      | **Novel systemic therapy for SCLC**                                              |
|                  | Byoung Chul Cho, Korea                                                            |
| 14:25-14:50      | **Genomic study for SCLC: Is this a waste of time?**                             |
|                  | David Carbone, USA                                                                |
| 14:50-15:15      | **Is PCI still indicated**                                                       |
|                  | Chong Kin Liam, Malaysia                                                          |
| 15:15-15:40      | **Role of surgical resection and chemotherapy for T1-2N0 SCLC**                   |
|                  | Zhen-Fa Zhang, China                                                             |
| 15:40-16:00      | Discussion                                                                       |
| 16:00-16:20      | Coffee break                                                                     |
| 16:20-16:30      | **First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 mut/Mb): Results From CheckMate 227**  
                   Keunchil Park, Korea                                                            |
| 16:30-16:40      | **A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor**  
                   Yi-Long Wu, China                                                               |
| 16:40-17:00      | Discussant                                                                       |
|                  | Hui Li, China                                                                     |
| 17:30-19:00      | **Type: Satellite Symposia**                                                     |
|                  | **Title: Symposium Supported by Bristol-Myers Squibb - Jade Ballroom**           |
|                  | **Type: Satellite Symposia**                                                     |
|                  | **Title: Symposium Supported by Shanghai Tongshu - Crystal Ballroom 1**          |
## Saturday, November 10, 2018

### Parallel Session 1 – Crystal Ballroom 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:55</td>
<td>Oligomatastasis: what is optimal treatment?</td>
<td>Cai-Cun Zhou, China</td>
</tr>
<tr>
<td>8:55-9:20</td>
<td>Oligomatastasis Surgical Oncologist Perspective</td>
<td>Xue-Ning Yang, China</td>
</tr>
<tr>
<td>9:20-9:45</td>
<td>Oligomatastasis Radiation Oncologist Perspective</td>
<td>Cong-Ying Xie, China</td>
</tr>
<tr>
<td>9:45-10:10</td>
<td>Oligomatastasis – Real world cases for MDT</td>
<td>Xiu-Yu Cai, China</td>
</tr>
<tr>
<td>10:10-10:35</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:35-10:55</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

### Special Symposia: Microvascular treatment of lung cancer, for long-term stability

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55-11:20</td>
<td>Grand plan, Bev leading the future</td>
<td>Li-Fang Wang, China</td>
</tr>
<tr>
<td>11:20-11:45</td>
<td>Anti-angiogenic small molecular targeting drugs, now and future</td>
<td>Hong-Yun Zhao, China</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Parallel Session 2 – Crystal Ballroom 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:55</td>
<td>Translational research for in early stage NSCLC</td>
<td>Hai-Quan Chen, China</td>
</tr>
<tr>
<td>8:55-9:20</td>
<td>Biomarker testing: where we are and where do we go from here?</td>
<td>Bob T. Li, USA</td>
</tr>
<tr>
<td>9:20-9:45</td>
<td>Translational research for in late stage NSCLC</td>
<td>Bei-Li Gao, China</td>
</tr>
<tr>
<td>9:45-10:10</td>
<td>Clinical Research in China</td>
<td>Zhi-Yong Ma, China</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>10:10-10:35</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:35-10:55</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>
| 10:55-11:20 | **Special Symposia: Hotspots of Lung Cancer Translational Research**  
Co-Chairs: Jie Jiang, China; Hai-Yan Tu, China |
| 11:20-11:45 | **Biomarkers for immunotherapy**  
Chun-Xia Su, China |
| 11:45-12:00 | Discussion                                             |

**Parallel Session 3 – Jade Ballroom**

- **Early stage lung cancer: SBRT vs. surgery**  
  Zheng-Fei Zhu, China  
  8:30-8:55
- **The role of surgical management in the treatment of non-small cell lung cancer**  
  Gui-Bin Qiao, China  
  8:55-9:20
- **A genomic study: How to Improve limit of detection of lung cancer liquid biopsy**  
  Xiao-Nan Wang, China  
  9:20-9:45
- **How to deal with multiple pulmonary nodules**  
  Wei-Min Li, China  
  9:45-10:10
- **Discussion**  
  10:10-10:35
- **Coffee break**  
  10:35-10:55

**Special Symposia: What's new in the management of Squamous lung cancer?**  
Chair: Jin-Ji Yang, China  
10:55-11:20

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:55-11:20 | What we have known of the tumor and immuno biology of Squamous lung cancer?  
Ming-Fang Zhao, China |
| 11:20-11:45 | **Breakthrough in treating Squamous lung cancer: Current clinical progression and future perspectives**  
Hai-Hong Yang, China |
| 11:45-12:00 | Discussion                                             |

Official Language: The official language of ACLC 2018 is English on November 8 and November 9. No simultaneous translation will be available. The official languages on November 10 will be in English and Chinese.